Skip to content
Research Article Open access CC BY 4.0

Pharmacovigilance: There is a Need for All to Get Involved!

Emmanuel M. Baah

Asian Journal of Research in Medical and Pharmaceutical Sciences · pp. 1–11 · Published 3 Oct 2018

10.9734/AJRIMPS/2018/44156

Abstract

The harm(s) a drug may cause may not be known at the time it gains market authorisation. Drug regulatory agencies weigh the benefits that the drug presents against the potential harms it could pose and allow it to be marketed if it is believed that the drug has a favourable risk-benefit ratio. Regulatory agencies then evaluate the drug’s risk profile as it is used on a large scale and institute remedial measures if found necessary. Data is needed in establishing that an Adverse Event (AE) accompanying drug use is, in fact, an Adverse Drug Reaction (ADR), and in carrying out the functions outlined above. This paper explores some of the issues involved, the importance of data in the work of regulatory agencies and draws attention to the need for all to facilitate the work of regulatory agencies.  

Adverse Event (AE) Adverse Drug Reaction (ADRs) Sponsors Spontaneous Reporting System (SRS) pharmacovigilance Ghana

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.